Yoonseon Park

Yoonseon Park

Auto-generated profile, based on publicly available information

Yoonseon Park

Division of Infectious Diseases, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
EJEun-Jeong Joo
Eun-Jeong Joo
JKJae-Hoon Ko
Jae-Hoon Ko
SKSeong Eun Kim
Seong Eun Kim
SKSeung ji Kang
Seung ji Kang
JBJi Hyeon Baek
Ji Hyeon Baek
KPKyong Ran Peck
Kyong Ran Peck
Joo EJ, et al. J Korean Med Sci. 2021 Mar;36(11):e83. https://doi.org/10.3346/jkms.2021.36.e83

1 January 2023 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
HSHye Jin Shi
Hye Jin Shi
JYJinyoung Yang
Jinyoung Yang
JEJoong Sik Eom
Joong Sik Eom
JKJae-Hoon Ko
Jae-Hoon Ko
KPKyong Ran Peck
Kyong Ran Peck
YPYoonseon Park
Yoonseon Park
Shi HJ, et al. J Korean Med Sci. 2023 Jun;38(28):e217. https://doi.org/10.3346/jkms.2023.38.e217

1 May 2020 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
JLJin Seo Lee
Jin Seo Lee
MLMi Suk Lee
Mi Suk Lee
YPYoonseon Park
Yoonseon Park
JLJacob Lee
Jacob Lee
EJEun-Jeong Joo
Eun-Jeong Joo
JEJoong Sik Eom
Joong Sik Eom
Purpose: To compare the clinical efficacy between peramivir and oseltamivir in hospitalized patients with influenza. Patients and Methods: Retrospective cohort study examined data from 542 adult patients with laboratory-confirmed seasonal influenza hospitalized in five teaching hospitals and one secondary hospital between August 2017 and May 2018. The main outcome was the defervescence rate within 3 days from the first administration of peramivir or oseltamivir. The secondary outcomes were mortality and duration of hospitalization/intensive care unit (ICU) stay. Results: Of the 542 enrolled patients, 251 were administered the standard dose of peramivir (300 mg, single dose), 42 were administered peramivir at doses exceeding 300 mg, and 249 were administered oseltamivir (75 mg, twice daily for 5 days). There were more ICU and pneumonia cases and older patients in the peramivir group, especially the high-dose group. The Charlson comorbidity index (CCI) scores were similar among the three groups. There were no significant differences in defervescence rates within 3 days between the three groups. The mortality and duration of hospital and ICU stays also did not differ significantly. The factors associated with 30-day mortality were ICU admission, high CCI score, and pneumonia. Conclusion: Treatment of influenza with either peramivir or oseltamivir in hospitalized adults resulted in generally similar clinical outcomes. Peramivir treatment showed good clinical response in influenza patients with pneumonia or admitted to the ICU.

1 January 2013 in Internal Medicine
Verified
Journal Article
Open access
PDF file
JAJin Young Ann
Jin Young Ann
JKJae-Cheol Kwon
Jae-Cheol Kwon
JSJe Eun Song
Je Eun Song
MKMin Hyung Kim
Min Hyung Kim
DODong Hyun Oh
Dong Hyun Oh
DKDu-young Kang
Du-young Kang
Infections caused by Gemella morbillorum are uncommon. This organism is primarily associated with endocarditis and bacteremia and rarely with spondylodiscitis, arthritis, hepatic abscesses and meningitis. Sternal osteomyelitis caused by G. morbillorum has not yet been reported. We herein present a case of sternal osteomyelitis with a mediastinal abscess caused by G. morbillorum that occurred in a 74-year-old diabetic patient following blunt force trauma to the anterior chest wall. The patient was treated successfully with surgical excision and prolonged antibiotic treatment. Early recognition and timely intervention are important for managing life-threatening osteomyelitis of the sternum.

13 March 2023 in Infection & Chemotherapy
Verified
Journal Article
Open access
NKNam Yee Kim
Nam Yee Kim
HSHye Jin Shi
Hye Jin Shi
SOSung-Suck Oh
Sung-Suck Oh
YGYoung-Woo Gong
Young-Woo Gong
MKMun-Ju Kwon
Mun-Ju Kwon
YPYoonseon Park
Yoonseon Park
Kim NY, et al. Infect Chemother. 2023 Mar;55:e10. https://doi.org/10.3947/ic.2022.0152

15 July 2022 in Infection & Chemotherapy
Verified
Journal Article
Open access
SHShin Hee Hong
Shin Hee Hong
HSHye Jin Shi
Hye Jin Shi
SKSuk Young Kim
Suk Young Kim
YPYoonseon Park
Yoonseon Park
JEJoong Sik Eom
Joong Sik Eom
Hong SH, et al. Infect Chemother. 2022 Jul;54:e52. https://doi.org/10.3947/ic.2022.0072